久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Oncternal Announces First Patient Dosed in Cirmtuzumab, Paclitaxel Trial americanpharmaceuticalreview
    September 13, 2018
    Oncternal Therapeutics announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advan

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service